KINTARA THERAPEUTICS INC (KTRA)

US49720K2006 - Common Stock

0.2154  -0.01 (-6.31%)

After market: 0.225 +0.01 (+4.46%)

Fundamental Rating

2

KTRA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. KTRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KTRA does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KTRA has reported negative net income.
KTRA had a negative operating cash flow in the past year.
KTRA had negative earnings in each of the past 5 years.
In the past 5 years KTRA always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -137.12%, KTRA is not doing good in the industry: 84.01% of the companies in the same industry are doing better.
KTRA has a worse Return On Equity (-226.35%) than 70.69% of its industry peers.
Industry RankSector Rank
ROA -137.12%
ROE -226.35%
ROIC N/A
ROA(3y)-224%
ROA(5y)-257.81%
ROE(3y)-832.26%
ROE(5y)-1280.11%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KTRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

KTRA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, KTRA has more shares outstanding
There is no outstanding debt for KTRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -37.01, we must say that KTRA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -37.01, KTRA is not doing good in the industry: 91.83% of the companies in the same industry are doing better.
There is no outstanding debt for KTRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -37.01
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 2.45 indicates that KTRA has no problem at all paying its short term obligations.
With a Current ratio value of 2.45, KTRA is not doing good in the industry: 72.11% of the companies in the same industry are doing better.
KTRA has a Quick Ratio of 2.45. This indicates that KTRA is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.45, KTRA is not doing good in the industry: 70.87% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.45

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.09% over the past year.
EPS 1Y (TTM)77.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KTRA will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.35% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y17.39%
EPS Next 2Y9.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KTRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KTRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.35%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KTRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KINTARA THERAPEUTICS INC

NASDAQ:KTRA (10/17/2024, 8:46:26 PM)

After market: 0.225 +0.01 (+4.46%)

0.2154

-0.01 (-6.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-09 2024-10-09/amc
Earnings (Next)11-11 2024-11-11/amc
Inst Owners1.51%
Inst Owner Change2.3%
Ins Owners5.59%
Ins Owner Change74.64%
Market Cap11.99M
Analysts43.33
Price Target14.28 (6529.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)-73.53%
DP-0.07%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.19
P/tB 3.19
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -137.12%
ROE -226.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-224%
ROA(5y)-257.81%
ROE(3y)-832.26%
ROE(5y)-1280.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.36%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 2.45
Altman-Z -37.01
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)139.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.86%
EPS Next Y17.39%
EPS Next 2Y9.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.55%
OCF growth 3YN/A
OCF growth 5YN/A